The LOTEMAX (loteprednol etabonate ophthalmic gel) gel is described as a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Loteprednol etabonate, the active ingredient in LOTEMAX gel, was first approved as an ocular anti-inflammatory agent by FDA in 1998.
Related Articles on Ophthalmology:
Ophthalmologist on the Move: Dr. Steven Brady Joins WA’s Cascade Eye & Skin Centers
Ophthalmologist Dr. Robert Massof Receives ‘Champion of Change’ Honor at White House
Global Ophthalmology Devices Market Projected to Reach $18B in 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
